Cancer Doctors Ring Up Big Bills for Tarnished Drug
Many oncologists now use a drug called Procrit sparingly, after regulators raised concerns about it. One group of Florida doctors stands out for how much it bills Medicare for the pricey drug. (Source: WSJ.com: Health)
Source: WSJ.com: Health - June 20, 2014 Category: Pharmaceuticals Tags: PAID Source Type: news
Procrit - Epoetin Alfa – Drug To Boost...
Procrit is a man-made protein, given as a booster shot to help restart red blood cell production when chemotherapy for breast cancer causes anemia. Procrit is a very safe drug, and has few risks and side effects. (Source: About.com Breast Cancer)
Source: About.com Breast Cancer - April 29, 2014 Category: Cancer & Oncology Authors: breastcancer.guide at about.com Tags: health Source Type: news
Epoetin Alfa Market & Erythropoietin Industry in China 2018...
ChinaMarketResearchReports.com adds Latest Report on “Investigation Report on China Epoetin Alfa Market, 2009-2018” to its store.(PRWeb March 11, 2014)Read the full story at http://www.prweb.com/releases/2018-china-epoetin-alfa/epo-industry-report/prweb11658217.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - March 13, 2014 Category: Pharmaceuticals Source Type: news
Anemia in breast cancer patients reduced by epoetin alfa with no negative impact on survival
In patients with high-risk breast cancer, addition of the erythropoiesis-stimulating agent (ESA) epoetin alfa to the chemotherapy regimen may help avoid the decrease in hemoglobin levels and resulting anemia often seen in these patients and does not negatively affect relapse-free (RFS) or overall survival (OS). However, it can increase the risk of thrombotic events, according to a study published in the Journal of the National Cancer Institute. To investigate the safety and efficacy of epoetin alfa, Volker Moebus, M.D... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - July 19, 2013 Category: Consumer Health News Tags: Breast Cancer Source Type: news
Epoetin alfa reduces anemia in breast cancer patients with no negative impact on survival
(Journal of the National Cancer Institute) In patients with high-risk breast cancer, addition of the erythropoiesis-stimulating agent epoetin alfa to the chemotherapy regimen may help avoid the decrease in hemoglobin levels and resulting anemia often seen in these patients and does not negatively affect relapse-free or overall survival. However, it can increase the risk of thrombotic events, according to a study published July 17 in the Journal of the National Cancer Institute. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 17, 2013 Category: Cancer & Oncology Source Type: news
Procrit - Epoetin Alfa – Drug To Boost...
Procrit is a man-made protein, given as a booster shot to help restart red blood cell production when chemotherapy for breast cancer causes anemia. Procrit is a very safe drug, and has few risks and side effects. (Source: About.com Breast Cancer)
Source: About.com Breast Cancer - July 7, 2013 Category: Cancer & Oncology Authors: breastcancer.guide at about.com Tags: health Source Type: news
Amgen Fraud Suit to Proceed as Class-Action
The U.S. Supreme Court shot down an effort by Epogen-maker Amgen to disqualify a securities fraud case as a class-action suit, sending the claims back to a lower court. (Source: WSJ.com: Health)
Source: WSJ.com: Health - February 27, 2013 Category: Pharmaceuticals Tags: PAID Source Type: news
NCCN Updates Cancer- and Treatment-Related Anemia Guidelines
FORT WASHINGTON, Pa., December 20, 2007 — The National Comprehensive Cancer Network (NCCN) announces important updates to the NCCN Cancer- and Treatment-Related Anemia Guidelines relating to the use of erythropoietin-stimulating agents (ESAs), such as epoetin alfa and darbepoetin alfa.
ESAs are no longer recommended for the treatment of cancer-related anemia associated with solid tumors or hematologic malignancies other than myelodysplastic syndromes (MDS). ESA therapy is an option for patient... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - December 20, 2007 Category: Cancer & Oncology Source Type: news
